Xenon ( (XENE) ) just unveiled an update.
On February 24, 2025, Sherry Aulin announced her resignation as CFO of Xenon Pharmaceuticals, effective June 30, 2025, for personal reasons, with no disputes related to the company’s operations. She will continue as an advisor until August 31, 2025, while the company searches for her replacement. Xenon also reported its financial results for 2024 and provided a business update, highlighting its ongoing and planned clinical trials for azetukalner in epilepsy and neuropsychiatric disorders. The company anticipates a catalyst-rich period in the next 12 to 24 months, with multiple regulatory filings and potential commercial launches. Despite a net loss increase in 2024, Xenon maintains a strong cash position to fund operations into 2027.
More about Xenon
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need. The company is involved in the development of treatments for neurological and neuropsychiatric conditions, with a focus on epilepsy and major depressive disorder. Xenon is advancing its pipeline with late-stage clinical programs and early-stage development candidates targeting potassium and sodium channels.
YTD Price Performance: -2.66%
Average Trading Volume: 404,605
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.98B
Find detailed analytics on XENE stock on TipRanks’ Stock Analysis page.